Announcement PDF RNS Number : 4080E Fusion Antibodies PLC 03 July 2019 03 July 2019 Fusion Antibodies plc ("Fusion" or the "Company") Director/PDMR Shareholding Fusion Antibodies plc (AIM: FAB), a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces the following purchases of ordinary shares in the Company ("Ordinary Shares") by certain directors. On 02 July 2019, Dr Paul Kerr, Chief Executive Officer, purchased 6,920 Ordinary Shares at a price of 72.896 pence per Ordinary Share. Following this purchase, Paul Kerr has a direct and indirect interest in 540,710 Ordinary Shares, representing approximately 2.45 per cent. of the Company's issued share capital. On 02 July 2019, Alan Mawson, Non-Executive Director, purchased 10,000 Ordinary Shares into his pension fund at a price of 59 pence per Ordinary Share. Following this purchase, Alan Mawson has a direct and indirect interest in 53,988 Ordinary Shares, representing approximately 0.24 per cent. of the Company's issued share capital. Alan Mawson is also a NonExecutive Director of Clarendon Fund Managers Limited ("Clarendon") and sits on Clarendon's investment committee. Clarendon is the fund manager for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and Viridian Growth Fund LP which holds 1,831,500 Ordinary Shares. On 02 July 2019, Sonya Ferguson, Non-Executive Director, purchased 30,000 Ordinary Shares at a price of 69.5 pence per Ordinary Share. Following this purchase, Sonya Ferguson has a direct and indirect interest in 60,900 Ordinary Shares, representing approximately 0.28 per cent. of the Company's issued share capital. The following notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details. 1 a) 2 a) Details of the person discharging managerial responsibilities / person closely associated Name Dr Paul Kerr Reason for the notification Position/status Chief Executive Officer b) 3 a) b) 4 a) b) c) d) e) f) 1 a) 2 a) b) 3 a) b) 4 a) Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name Fusion Antibodies plc LEI 213800KBAYRC9VOQ9V39 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Ordinary shares of 4p each in Fusion Antibodies plc financial instrument, type of instrument Identification code (ISIN) for Fusion Antibodies plc Identification code ordinary shares: GB00BDQZGK16 Nature of the transaction Price(s) and volume(s) Purchase of shares Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction N/A Price(s) Volume(s) 72.896p 6,920 02 July 2019 London Stock Exchange, XLON Details of the person discharging managerial responsibilities / person closely associated Name Alan Mawson Reason for the notification Position/status Non-Executive Director Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name Fusion Antibodies plc LEI 213800KBAYRC9VOQ9V39 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Ordinary shares of 4p each in Fusion Antibodies plc financial instrument, b) c) d) e) f) 1 a) 2 a) b) 3 a) b) 4 a) b) c) type of instrument Identification code Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 Nature of the transaction Price(s) and volume(s) Purchase of shares Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction N/A Price(s) Volume(s) 59p 10,000 02 July 2019 London Stock Exchange, XLON Details of the person discharging managerial responsibilities / person closely associated Name Sonya Ferguson Reason for the notification Position/status Non-Executive Director Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name Fusion Antibodies plc LEI 213800KBAYRC9VOQ9V39 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the Ordinary shares of 4p each in Fusion Antibodies plc financial instrument, type of instrument Identification code (ISIN) for Fusion Antibodies plc Identification code ordinary shares: GB00BDQZGK16 Nature of the transaction Price(s) and volume(s) Purchase of shares Price(s) Volume(s) 69.5p 30,000 d) e) f) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction N/A 02 July 2019 London Stock Exchange, XLON Enquiries: Fusion Antibodies plc Dr Paul Kerr, Chief Executive Officer James Fair, Chief Financial Officer www.fusionantibodies.com Allenby Capital Limited James Reeve / Asha Chotai Tel: +44 (0)20 3328 5656 Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com Mob: +44 (0)7980 541 893 Mob: +44 (0)7876 741 001 Paul McManus Anna Dunphy Via Walbrook PR About Fusion Antibodies plc Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The Company has a highly experienced management team with a combined 47 years' experience in the biopharma industry. The global monoclonal antibody therapeutics market, which accounted for 43 per cent. of the global biologics market in 2016, was valued at between $85.4 billion and $86.7 billion in 2015 and is forecast to increase at a CAGR of between 8.2 per cent. and 12.2 per cent. for the period 2016 to 2024. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END DSHSSIFIDFUSESW